Brief: HLS Therapeutics Supports Trial To Investigate Effects Of Vascepa Against COVID-19
21/05/2020 21:33
May 21 (Reuters) - HLS Therapeutics Inc HLS.TO :
* HLS THERAPEUTICS SUPPORTS TRIAL TO INVESTIGATE THE EFFECTS
OF
VASCEPA® (ICOSAPENT ETHYL) AGAINST COVID-19
* HLS THERAPEUTICS INC - IN COLLABORATION WITH AMARIN, IT IS
SUPPORTING A TRIAL TO INVESTIGATE EFFECTS OF VASCEPA
Source text for Eikon: ID:nCNWPwgHva
Further company coverage: HLS.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HLS Therapeutics
See all newsBrief: Hls Therapeutics Increases Normal Course Issuer Bid
Brief: HLS Therapeutics Announces Q2 2026 Financial Results
Canada's HLS Therapeutics Q2 revenue rises on higher cardiovascular drugs demand
Brief: HLS Therapeutics - Secures Nilemdo Reimbursement With Private Payers Covering 80% Of Privately Insured Canadians
Canada Research Roundup: CIBC ,HLS Therapeutics, TD Bank Group